<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03981484</url>
  </required_header>
  <id_info>
    <org_study_id>00001</org_study_id>
    <nct_id>NCT03981484</nct_id>
  </id_info>
  <brief_title>REPlaCE- Randomized Trial Evaluating the Use of Prothrombin Complex concEntrate to Improve Survival in Patients With Traumatic Coagulopathy</brief_title>
  <acronym>REPLaCE</acronym>
  <official_title>REPlaCE- Randomized Trial Evaluating the Use of Prothrombin Complex concEntrate to Improve Survival in Patients With Traumatic Coagulopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bellal A. Joseph, MD, FACS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Arizona</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Uncontrolled hemorrhage continues to be a significant source of mortality for trauma
      patients. Their condition is further complicated by Trauma Induced Coagulopathy (TIC), which
      makes it more difficult to control bleeding due to coagulation factor deficiency. Prothrombin
      Complex Concentrate (PCC) is thought to be a promising treatment option. This phase II
      clinical trial evaluates the use of 4-Factor PCC in addition to standard resuscitation
      methods compared to standard resuscitation methods alone in patients with TIC. Patients will
      be randomized at a 1:1 ratio. The primary endpoint of this trial will be 30 day mortality.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2020</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>24 Hour Mortality</measure>
    <time_frame>24 hours after enrollment</time_frame>
    <description>Assess if patient is alive at 24 hours post treatment</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Coagulopathy</condition>
  <condition>Hemorrhage</condition>
  <arm_group>
    <arm_group_label>PCC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose of 4-Factor PCC in addition to standard resuscitation methods</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>standard resuscitation methods only</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Prothrombin Complex Concentrate</intervention_name>
    <description>single dose of 25 IU/kg of 4-PCC at time of enrollment</description>
    <arm_group_label>PCC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Whole Blood, Plasma, Packed Red Blood Cells</intervention_name>
    <description>site's standard resuscitation protocol</description>
    <arm_group_label>Standard of Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. ≥15 years old

          2. anticipate giving 4+ units based on Revised Assessment of Bleeding and Transfusion
             score ≥ 2

        Exclusion Criteria:

          1. Cardiopulmonary Resuscitation &gt; 5 minutes

          2. Penetrating cranial injury or exposed brain matter

          3. Anticoagulation treatment

          4. Transfer patients

          5. Known pregnancy

          6. Prisoners
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bellal Joseph, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arizona</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrea Seach, BS</last_name>
    <phone>520-626-2876</phone>
    <email>aseach@surgery.arizona.edu</email>
  </overall_contact>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 6, 2019</study_first_submitted>
  <study_first_submitted_qc>June 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 10, 2019</study_first_posted>
  <last_update_submitted>June 7, 2019</last_update_submitted>
  <last_update_submitted_qc>June 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Arizona</investigator_affiliation>
    <investigator_full_name>Bellal A. Joseph, MD, FACS</investigator_full_name>
    <investigator_title>Chief of the Division of Trauma, Acute Care, Burn, and Emergency Surgery</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemostatic Disorders</mesh_term>
    <mesh_term>Blood Coagulation Disorders</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

